Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Apr 2;16(1):235. doi: 10.1038/s41419-025-07528-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2025

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a The TCGA database of Sangerbox 3.0 was used to analyze the expression levels of NAT10 in KIRC cancer tissues (n = 531) and normal tissues (n = 72). b QRT-PCR was used to detect NAT10 mRNA levels in 15 pairs of ccRCC cancer tissues and adjacent para-cancer tissues. c Left: Representative images of in situ NAT10 expression levels in 68 pairs of ccRCC cancer tissues and adjacent tissues detected by immunohistochemical staining. Scale: 50 μm (left); 20 μm (right). Statistical analysis of the intensity of immunohistochemical staining (right). d Kaplan–Meier analysis survival for ccRCC patients based on NAT10 expression (n = 261, p = 0.0026, log-rank test). e UALCAN was used to analyze the expression level of NAT10 in normal tissues and in each stage of ccRCC. f Comparison of expression levels of NAT10 in ccRCC WHO/ISUP stage I and IV by immunohistochemical staining. WHO/ISUP stage I(above), WHO/ISUP stage IV(below). Scale: 50 μm(left); 20 μm(right). g Statistical analysis of the intensity of immunohistochemical staining.